A phase 2 dose-finding study of namilumab in combination with methotrexate (NEXUS; NCT02379091) is now ongoing in patients with moderate-to-severe RA who have responded inadequately to methotrexate or an anti-tumor necrosis factor inhibitor. This evidence concerns the gene TNF and rheumatoid arthritis.